Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer - Abstract

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.


Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

Written by:
Antonarakis ES, Armstrong AJ.   Are you the author?

Reference: Prostate Cancer Prostatic Dis. 2011 May 17. Epub ahead of print.
doi: 10.1038/pcan.2011.24

PubMed Abstract
PMID: 21577233

UroToday.com Prostate Cancer Section



email news signup